#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Cocaine	_
1-2	8-18	dependence	_
1-3	19-22	and	_
1-4	23-31	thalamic	_
1-5	32-42	functional	_
1-6	43-55	connectivity	_
1-7	56-57	:	_
1-8	58-59	a	_
1-9	60-72	multivariate	_
1-10	73-80	pattern	_
1-11	81-89	analysis	_
1-12	90-97	Cocaine	_
1-13	98-108	dependence	_
1-14	109-111	is	_
1-15	112-122	associated	_
1-16	123-127	with	_
1-17	128-136	deficits	_
1-18	137-139	in	_
1-19	140-149	cognitive	_
1-20	150-157	control	_
1-21	158-159	.	_

2-1	160-168	Previous	_
2-2	169-176	studies	_
2-3	177-189	demonstrated	_
2-4	190-194	that	_
2-5	195-202	chronic	_
2-6	203-210	cocaine	_
2-7	211-214	use	_
2-8	215-222	affects	_
2-9	223-226	the	_
2-10	227-235	activity	_
2-11	236-239	and	_
2-12	240-250	functional	_
2-13	251-263	connectivity	_
2-14	264-266	of	_
2-15	267-270	the	_
2-16	271-279	thalamus	_
2-17	280-281	,	_
2-18	282-283	a	_
2-19	284-295	subcortical	_
2-20	296-305	structure	_
2-21	306-314	critical	_
2-22	315-318	for	_
2-23	319-328	cognitive	_
2-24	329-340	functioning	_
2-25	341-342	.	_

3-1	343-350	However	_
3-2	351-352	,	_
3-3	353-356	the	_
3-4	357-365	thalamus	_
3-5	366-374	contains	_
3-6	375-381	nuclei	_
3-7	382-395	heterogeneous	_
3-8	396-398	in	_
3-9	399-408	functions	_
3-10	409-410	,	_
3-11	411-414	and	_
3-12	415-417	it	_
3-13	418-420	is	_
3-14	421-424	not	_
3-15	425-430	known	_
3-16	431-434	how	_
3-17	435-443	thalamic	_
3-18	444-454	subregions	_
3-19	455-465	contribute	_
3-20	466-468	to	_
3-21	469-478	cognitive	_
3-22	479-491	dysfunctions	_
3-23	492-494	in	_
3-24	495-502	cocaine	_
3-25	503-513	dependence	_
3-26	514-515	.	_

4-1	516-518	To	_
4-2	519-526	address	_
4-3	527-531	this	_
4-4	532-537	issue	_
4-5	538-539	,	_
4-6	540-542	we	_
4-7	543-547	used	_
4-8	548-560	multivariate	_
4-9	561-568	pattern	_
4-10	569-577	analysis	_
4-11	578-579	(	_
4-12	580-584	MVPA	_
4-13	585-586	)	_
4-14	587-589	to	_
4-15	590-597	examine	_
4-16	598-601	how	_
4-17	602-612	functional	_
4-18	613-625	connectivity	_
4-19	626-628	of	_
4-20	629-632	the	_
4-21	633-641	thalamus	_
4-22	642-655	distinguishes	_
4-23	656-659	100	_
4-24	660-677	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-25	678-690	participants	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-26	691-692	(	_
4-27	693-695	CD	_
4-28	696-697	)	_
4-29	698-702	from	_
4-30	703-706	100	_
4-31	707-722	demographically	_
4-32	723-730	matched	_
4-33	731-738	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-34	739-746	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-35	747-758	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-36	759-760	(	_
4-37	761-763	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-38	764-765	)	_
4-39	766-767	.	_

5-1	768-770	We	_
5-2	771-784	characterized	_
5-3	785-788	six	_
5-4	789-801	task-related	_
5-5	802-810	networks	_
5-6	811-815	with	_
5-7	816-827	independent	_
5-8	828-837	component	_
5-9	838-846	analysis	_
5-10	847-849	of	_
5-11	850-854	fMRI	_
5-12	855-859	data	_
5-13	860-862	of	_
5-14	863-864	a	_
5-15	865-869	stop	_
5-16	870-876	signal	_
5-17	877-881	task	_
5-18	882-885	and	_
5-19	886-894	employed	_
5-20	895-899	MVPA	_
5-21	900-902	to	_
5-22	903-914	distinguish	_
5-23	915-917	CD	_
5-24	918-922	from	_
5-25	923-925	HC	_
5-26	926-928	on	_
5-27	929-932	the	_
5-28	933-938	basis	_
5-29	939-941	of	_
5-30	942-952	voxel-wise	_
5-31	953-961	thalamic	_
5-32	962-974	connectivity	_
5-33	975-977	to	_
5-34	978-981	the	_
5-35	982-985	six	_
5-36	986-997	independent	_
5-37	998-1008	components	_
5-38	1009-1010	.	_

6-1	1011-1013	In	_
6-2	1014-1016	an	_
6-3	1017-1025	unbiased	_
6-4	1026-1031	model	_
6-5	1032-1034	of	_
6-6	1035-1043	distinct	_
6-7	1044-1052	training	_
6-8	1053-1056	and	_
6-9	1057-1064	testing	_
6-10	1065-1069	data	_
6-11	1070-1071	,	_
6-12	1072-1075	the	_
6-13	1076-1084	analysis	_
6-14	1085-1094	correctly	_
6-15	1095-1105	classified	_
6-16	1106-1108	72	_
6-17	1109-1110	%	_
6-18	1111-1113	of	_
6-19	1114-1122	subjects	_
6-20	1123-1127	with	_
6-21	1128-1141	leave-one-out	_
6-22	1142-1158	cross-validation	_
6-23	1159-1160	(	_
6-24	1161-1162	p	_
6-25	1163-1164	<	_
6-26	1165-1170	0.001	_
6-27	1171-1172	)	_
6-28	1173-1174	,	_
6-29	1175-1183	superior	_
6-30	1184-1186	to	_
6-31	1187-1197	comparison	_
6-32	1198-1203	brain	_
6-33	1204-1211	regions	_
6-34	1212-1216	with	_
6-35	1217-1224	similar	_
6-36	1225-1230	voxel	_
6-37	1231-1237	counts	_
6-38	1238-1239	(	_
6-39	1240-1241	p	_
6-40	1242-1243	<	_
6-41	1244-1249	0.004	_
6-42	1250-1251	,	_
6-43	1252-1262	two-sample	_
6-44	1263-1264	t	_
6-45	1265-1269	test	_
6-46	1270-1271	)	_
6-47	1272-1273	.	_

7-1	1274-1282	Thalamic	_
7-2	1283-1289	voxels	_
7-3	1290-1294	that	_
7-4	1295-1299	form	_
7-5	1300-1303	the	_
7-6	1304-1309	basis	_
7-7	1310-1312	of	_
7-8	1313-1327	classification	_
7-9	1328-1337	aggregate	_
7-10	1338-1340	in	_
7-11	1341-1349	distinct	_
7-12	1350-1361	subclusters	_
7-13	1362-1363	,	_
7-14	1364-1374	suggesting	_
7-15	1375-1379	that	_
7-16	1380-1394	connectivities	_
7-17	1395-1397	of	_
7-18	1398-1406	thalamic	_
7-19	1407-1416	subnuclei	_
7-20	1417-1428	distinguish	_
7-21	1429-1431	CD	_
7-22	1432-1436	from	_
7-23	1437-1439	HC	_
7-24	1440-1441	.	_

8-1	1442-1449	Further	_
8-2	1450-1451	,	_
8-3	1452-1458	linear	_
8-4	1459-1470	regressions	_
8-5	1471-1479	provided	_
8-6	1480-1490	suggestive	_
8-7	1491-1499	evidence	_
8-8	1500-1503	for	_
8-9	1504-1505	a	_
8-10	1506-1517	correlation	_
8-11	1518-1520	of	_
8-12	1521-1524	the	_
8-13	1525-1533	thalamic	_
8-14	1534-1548	connectivities	_
8-15	1549-1553	with	_
8-16	1554-1562	clinical	_
8-17	1563-1572	variables	_
8-18	1573-1576	and	_
8-19	1577-1588	performance	_
8-20	1589-1597	measures	_
8-21	1598-1600	on	_
8-22	1601-1604	the	_
8-23	1605-1609	stop	_
8-24	1610-1616	signal	_
8-25	1617-1621	task	_
8-26	1622-1623	.	_

9-1	1624-1632	Together	_
9-2	1633-1634	,	_
9-3	1635-1640	these	_
9-4	1641-1649	findings	_
9-5	1650-1657	support	_
9-6	1658-1666	thalamic	_
9-7	1667-1674	circuit	_
9-8	1675-1686	dysfunction	_
9-9	1687-1689	in	_
9-10	1690-1699	cognitive	_
9-11	1700-1707	control	_
9-12	1708-1710	as	_
9-13	1711-1713	an	_
9-14	1714-1723	important	_
9-15	1724-1730	neural	_
9-16	1731-1737	marker	_
9-17	1738-1740	of	_
9-18	1741-1748	cocaine	_
9-19	1749-1759	dependence	_
9-20	1760-1761	.	_

10-1	1762-1772	Highlights	_
10-2	1773-1780	Cocaine	_
10-3	1781-1791	dependence	_
10-4	1792-1794	is	_
10-5	1795-1805	associated	_
10-6	1806-1810	with	_
10-7	1811-1819	thalamic	_
10-8	1820-1831	dysfunction	_
10-9	1832-1835	and	_
10-10	1836-1845	cognitive	_
10-11	1846-1854	deficits	_
10-12	1855-1856	.	_

11-1	1857-1860	The	_
11-2	1861-1869	thalamus	_
11-3	1870-1879	comprises	_
11-4	1880-1889	subnuclei	_
11-5	1890-1894	that	_
11-6	1895-1901	differ	_
11-7	1902-1904	in	_
11-8	1905-1914	cognitive	_
11-9	1915-1924	functions	_
11-10	1925-1926	.	_

12-1	1927-1931	MVPA	_
12-2	1932-1934	of	_
12-3	1935-1943	thalamic	_
12-4	1944-1956	connectivity	_
12-5	1957-1970	distinguishes	_
12-6	1971-1979	addicted	_
12-7	1980-1984	from	_
12-8	1985-1992	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-9	1993-2004	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-10	2005-2006	.	_

13-1	2007-2015	Thalamic	_
13-2	2016-2022	voxels	_
13-3	2023-2027	that	_
13-4	2028-2036	identify	_
13-5	2037-2044	addicts	_
13-6	2045-2054	aggregate	_
13-7	2055-2057	in	_
13-8	2058-2066	clusters	_
13-9	2067-2068	,	_
13-10	2069-2079	resembling	_
13-11	2080-2089	subnuclei	_
13-12	2090-2091	.	_

14-1	2092-2104	Connectivity	_
14-2	2105-2107	of	_
14-3	2108-2116	thalamic	_
14-4	2117-2125	clusters	_
14-5	2126-2134	reflects	_
14-6	2135-2143	specific	_
14-7	2144-2151	changes	_
14-8	2152-2154	in	_
14-9	2155-2158	SST	_
14-10	2159-2170	performance	_
14-11	2171-2172	.	_

15-1	2173-2182	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-2	2183-2186	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-3	2187-2194	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-4	2195-2203	Subjects	_
15-5	2204-2205	,	_
15-6	2206-2214	informed	_
15-7	2215-2222	consent	_
15-8	2223-2224	,	_
15-9	2225-2228	and	_
15-10	2229-2239	assessment	_
15-11	2240-2243	One	_
15-12	2244-2251	hundred	_
15-13	2252-2260	recently	_
15-14	2261-2270	abstinent	_
15-15	2271-2283	participants	_
15-16	2284-2285	(	_
15-17	2286-2288	62	_
15-18	2289-2292	men	_
15-19	2293-2294	)	_
15-20	2295-2299	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
15-21	2300-2307	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
15-22	2308-2318	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
15-23	2319-2320	(	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
15-24	2321-2323	CD	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
15-25	2324-2325	)	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
15-26	2326-2329	and	_
15-27	2330-2333	one	_
15-28	2334-2341	hundred	_
15-29	2342-2346	age-	_
15-30	2347-2350	and	_
15-31	2351-2365	gender-matched	_
15-32	2366-2373	healthy	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-33	2374-2379	adult	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-34	2380-2381	(	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-35	2382-2384	HC	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-36	2385-2386	)	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-37	2387-2395	subjects	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
15-38	2396-2397	(	_
15-39	2398-2400	55	_
15-40	2401-2404	men	_
15-41	2405-2406	)	_
15-42	2407-2419	participated	_
15-43	2420-2422	in	_
15-44	2423-2427	this	_
15-45	2428-2433	study	_
15-46	2434-2435	(	_
15-47	2436-2441	Table	_
15-48	2442-2443	1	_
15-49	2444-2445	)	_
15-50	2446-2447	.	_

16-1	2448-2450	CD	_
16-2	2451-2454	met	_
16-3	2455-2463	criteria	_
16-4	2464-2467	for	_
16-5	2468-2475	current	_
16-6	2476-2483	cocaine	_
16-7	2484-2494	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
16-8	2495-2496	,	_
16-9	2497-2499	as	_
16-10	2500-2509	diagnosed	_
16-11	2510-2512	by	_
16-12	2513-2516	the	_
16-13	2517-2527	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-14	2528-2536	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-15	2537-2546	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-16	2547-2550	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-17	2551-2557	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-18	2558-2559	.	_

17-1	2560-2566	Recent	_
17-2	2567-2574	cocaine	_
17-3	2575-2578	use	_
17-4	2579-2582	was	_
17-5	2583-2592	confirmed	_
17-6	2593-2595	by	_
17-7	2596-2601	urine	_
17-8	2602-2612	toxicology	_
17-9	2613-2620	screens	_
17-10	2621-2622	.	_

18-1	2623-2627	They	_
18-2	2628-2632	were	_
18-3	2633-2642	drug-free	_
18-4	2643-2648	while	_
18-5	2649-2656	staying	_
18-6	2657-2659	in	_
18-7	2660-2662	an	_
18-8	2663-2672	inpatient	_
18-9	2673-2677	unit	_
18-10	2678-2683	prior	_
18-11	2684-2686	to	_
18-12	2687-2690	the	_
18-13	2691-2698	current	_
18-14	2699-2703	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-15	2704-2709	study	_
18-16	2710-2711	.	_

19-1	2712-2715	All	_
19-2	2716-2724	subjects	_
19-3	2725-2729	were	_
19-4	2730-2740	physically	_
19-5	2741-2748	healthy	_
19-6	2749-2753	with	_
19-7	2754-2756	no	_
19-8	2757-2762	major	_
19-9	2763-2770	medical	_
19-10	2771-2780	illnesses	_
19-11	2781-2783	or	_
19-12	2784-2791	current	_
19-13	2792-2795	use	_
19-14	2796-2798	of	_
19-15	2799-2811	prescription	_
19-16	2812-2823	medications	_
19-17	2824-2825	.	_

20-1	2826-2830	None	_
20-2	2831-2839	reported	_
20-3	2840-2846	having	_
20-4	2847-2848	a	_
20-5	2849-2856	history	_
20-6	2857-2859	of	_
20-7	2860-2864	head	_
20-8	2865-2871	injury	_
20-9	2872-2874	or	_
20-10	2875-2887	neurological	_
20-11	2888-2895	illness	_
20-12	2896-2897	.	_

21-1	2898-2903	Other	_
21-2	2904-2913	exclusion	_
21-3	2914-2922	criteria	_
21-4	2923-2931	included	_
21-5	2932-2942	dependence	_
21-6	2943-2945	on	_
21-7	2946-2953	another	_
21-8	2954-2966	psychoactive	_
21-9	2967-2976	substance	_
21-10	2977-2978	(	_
21-11	2979-2985	except	_
21-12	2986-2994	nicotine	_
21-13	2995-2996	)	_
21-14	2997-3000	and	_
21-15	3001-3008	current	_
21-16	3009-3011	or	_
21-17	3012-3016	past	_
21-18	3017-3024	history	_
21-19	3025-3027	of	_
21-20	3028-3037	psychotic	_
21-21	3038-3047	disorders	_
21-22	3048-3049	.	_

22-1	3050-3061	Individuals	_
22-2	3062-3066	with	_
22-3	3067-3074	current	_
22-4	3075-3085	depressive	_
22-5	3086-3088	or	_
22-6	3089-3096	anxiety	_
22-7	3097-3105	symptoms	_
22-8	3106-3115	requiring	_
22-9	3116-3125	treatment	_
22-10	3126-3128	or	_
22-11	3129-3138	currently	_
22-12	3139-3144	being	_
22-13	3145-3152	treated	_
22-14	3153-3156	for	_
22-15	3157-3162	these	_
22-16	3163-3171	symptoms	_
22-17	3172-3176	were	_
22-18	3177-3185	excluded	_
22-19	3186-3188	as	_
22-20	3189-3193	well	_
22-21	3194-3195	.	_

23-1	3196-3199	The	_
23-2	3200-3205	Human	_
23-3	3206-3219	Investigation	_
23-4	3220-3229	committee	_
23-5	3230-3232	at	_
23-6	3233-3237	Yale	_
23-7	3238-3248	University	_
23-8	3249-3255	School	_
23-9	3256-3258	of	_
23-10	3259-3267	Medicine	_
23-11	3268-3276	approved	_
23-12	3277-3280	all	_
23-13	3281-3286	study	_
23-14	3287-3297	procedures	_
23-15	3298-3299	,	_
23-16	3300-3303	and	_
23-17	3304-3307	all	_
23-18	3308-3316	subjects	_
23-19	3317-3323	signed	_
23-20	3324-3326	an	_
23-21	3327-3335	informed	_
23-22	3336-3343	consent	_
23-23	3344-3349	prior	_
23-24	3350-3352	to	_
23-25	3353-3358	study	_
23-26	3359-3372	participation	_
23-27	3373-3374	.	_

24-1	3375-3377	CD	_
24-2	3378-3380	's	_
24-3	3381-3385	were	_
24-4	3386-3394	assessed	_
24-5	3395-3399	with	_
24-6	3400-3403	the	_
24-7	3404-3408	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-8	3409-3419	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-9	3420-3429	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-10	3430-3433	and	_
24-11	3434-3437	the	_
24-12	3438-3449	State-Trait	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-13	3450-3457	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-14	3458-3467	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-15	3468-3470	at	_
24-16	3471-3480	admission	_
24-17	3481-3482	.	_

25-1	3483-3486	The	_
25-2	3487-3491	mean	_
25-3	3492-3493	(	_
25-4	3494-3495	±	_
25-5	3496-3498	SD	_
25-6	3499-3500	)	_
25-7	3501-3504	BDI	_
25-8	3505-3506	(	_
25-9	3507-3511	12.2	_
25-10	3512-3513	±	_
25-11	3514-3517	8.9	_
25-12	3518-3519	)	_
25-13	3520-3523	and	_
25-14	3524-3528	STAI	_
25-15	3529-3534	state	_
25-16	3535-3536	(	_
25-17	3537-3541	36.2	_
25-18	3542-3543	±	_
25-19	3544-3548	10.7	_
25-20	3549-3550	)	_
25-21	3551-3554	and	_
25-22	3555-3560	trait	_
25-23	3561-3562	(	_
25-24	3563-3567	40.7	_
25-25	3568-3569	±	_
25-26	3570-3574	11.2	_
25-27	3575-3576	)	_
25-28	3577-3583	scores	_
25-29	3584-3588	were	_
25-30	3589-3595	within	_
25-31	3596-3599	the	_
25-32	3600-3605	range	_
25-33	3606-3614	reported	_
25-34	3615-3625	previously	_
25-35	3626-3629	for	_
25-36	3630-3641	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
25-37	3642-3646	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
25-38	3647-3654	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
25-39	3655-3665	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
25-40	3666-3667	.	_

26-1	3668-3675	Cocaine	_
26-2	3676-3683	craving	_
26-3	3684-3687	was	_
26-4	3688-3696	assessed	_
26-5	3697-3701	with	_
26-6	3702-3705	the	_
26-7	3706-3713	cocaine	_
26-8	3714-3721	craving	_
26-9	3722-3735	questionnaire	_
26-10	3736-3737	,	_
26-11	3738-3743	brief	_
26-12	3744-3751	version	_
26-13	3752-3753	(	_
26-14	3754-3763	CCQ-Brief	_
26-15	3764-3765	)	_
26-16	3766-3767	,	_
26-17	3768-3771	for	_
26-18	3772-3775	all	_
26-19	3776-3788	participants	_
26-20	3789-3794	every	_
26-21	3795-3798	two	_
26-22	3799-3801	to	_
26-23	3802-3807	three	_
26-24	3808-3812	days	_
26-25	3813-3814	.	_

27-1	3815-3818	The	_
27-2	3819-3828	CCQ-Brief	_
27-3	3829-3831	is	_
27-4	3832-3833	a	_
27-5	3834-3841	10-item	_
27-6	3842-3855	questionnaire	_
27-7	3856-3857	,	_
27-8	3858-3869	abbreviated	_
27-9	3870-3874	from	_
27-10	3875-3878	the	_
27-11	3879-3886	CCQ-Now	_
27-12	3887-3888	.	_

28-1	3889-3891	It	_
28-2	3892-3894	is	_
28-3	3895-3901	highly	_
28-4	3902-3912	correlated	_
28-5	3913-3917	with	_
28-6	3918-3921	the	_
28-7	3922-3929	CCQ-Now	_
28-8	3930-3933	and	_
28-9	3934-3939	other	_
28-10	3940-3947	cocaine	_
28-11	3948-3955	craving	_
28-12	3956-3964	measures	_
28-13	3965-3966	.	_

29-1	3967-3971	Each	_
29-2	3972-3976	item	_
29-3	3977-3980	was	_
29-4	3981-3986	rated	_
29-5	3987-3989	on	_
29-6	3990-3991	a	_
29-7	3992-3997	scale	_
29-8	3998-4002	from	_
29-9	4003-4004	1	_
29-10	4005-4007	to	_
29-11	4008-4009	7	_
29-12	4010-4011	,	_
29-13	4012-4016	with	_
29-14	4017-4018	a	_
29-15	4019-4025	higher	_
29-16	4026-4031	total	_
29-17	4032-4037	score	_
29-18	4038-4039	(	_
29-19	4040-4047	ranging	_
29-20	4048-4052	from	_
29-21	4053-4055	10	_
29-22	4056-4058	to	_
29-23	4059-4061	70	_
29-24	4062-4063	)	_
29-25	4064-4074	indicating	_
29-26	4075-4082	greater	_
29-27	4083-4090	craving	_
29-28	4091-4092	.	_

30-1	4093-4096	CDs	_
30-2	4097-4105	averaged	_
30-3	4106-4109	CCQ	_
30-4	4110-4116	scores	_
30-5	4117-4119	of	_
30-6	4120-4124	20.0	_
30-7	4125-4126	±	_
30-8	4127-4130	7.8	_
30-9	4131-4137	across	_
30-10	4138-4141	all	_
30-11	4142-4153	assessments	_
30-12	4154-4157	and	_
30-13	4158-4162	18.0	_
30-14	4163-4164	±	_
30-15	4165-4168	5.5	_
30-16	4169-4171	on	_
30-17	4172-4175	the	_
30-18	4176-4179	day	_
30-19	4180-4182	or	_
30-20	4183-4189	within	_
30-21	4190-4193	2–3	_
30-22	4194-4198	days	_
30-23	4199-4201	of	_
30-24	4202-4205	the	_
30-25	4206-4210	scan	_
30-26	4211-4212	.	_

31-1	4213-4216	The	_
31-2	4217-4225	majority	_
31-3	4226-4228	of	_
31-4	4229-4232	CDs	_
31-5	4233-4241	received	_
31-6	4242-4245	all	_
31-7	4246-4248	of	_
31-8	4249-4254	these	_
31-9	4255-4266	assessments	_
31-10	4267-4268	,	_
31-11	4269-4272	and	_
31-12	4273-4281	subjects	_
31-13	4282-4286	with	_
31-14	4287-4294	missing	_
31-15	4295-4299	data	_
31-16	4300-4304	were	_
31-17	4305-4308	not	_
31-18	4309-4317	included	_
31-19	4318-4320	in	_
31-20	4321-4324	the	_
31-21	4325-4336	correlation	_
31-22	4337-4345	analyses	_
31-23	4346-4347	(	_
31-24	4348-4351	see	_
31-25	4352-4357	below	_
31-26	4358-4359	)	_
31-27	4360-4361	.	_

32-1	4362-4372	Behavioral	_
32-2	4373-4377	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-3	4378-4381	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-4	4382-4386	scan	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-5	4387-4397	procedures	_
32-6	4398-4400	We	_
32-7	4401-4409	employed	_
32-8	4410-4411	a	_
32-9	4412-4423	stop-signal	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
32-10	4424-4428	task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
32-11	4429-4430	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
32-12	4431-4434	SST	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
32-13	4435-4436	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
32-14	4437-4439	as	_
32-15	4440-4448	detailed	_
32-16	4449-4451	in	_
32-17	4452-4455	our	_
32-18	4456-4464	previous	_
32-19	4465-4472	studies	_
32-20	4473-4474	.	_

33-1	4475-4482	Briefly	_
33-2	4483-4484	,	_
33-3	4485-4490	there	_
33-4	4491-4495	were	_
33-5	4496-4499	two	_
33-6	4500-4505	trial	_
33-7	4506-4511	types	_
33-8	4512-4513	:	_
33-9	4514-4515	“	_
33-10	4516-4518	go	_
33-11	4519-4520	”	_
33-12	4521-4524	and	_
33-13	4525-4526	“	_
33-14	4527-4531	stop	_
33-15	4532-4533	,	_
33-16	4534-4535	”	_
33-17	4536-4544	randomly	_
33-18	4545-4555	intermixed	_
33-19	4556-4557	.	_

34-1	4558-4559	A	_
34-2	4560-4565	small	_
34-3	4566-4569	dot	_
34-4	4570-4578	appeared	_
34-5	4579-4581	on	_
34-6	4582-4585	the	_
34-7	4586-4592	screen	_
34-8	4593-4595	to	_
34-9	4596-4602	engage	_
34-10	4603-4612	attention	_
34-11	4613-4615	at	_
34-12	4616-4619	the	_
34-13	4620-4629	beginning	_
34-14	4630-4632	of	_
34-15	4633-4634	a	_
34-16	4635-4637	go	_
34-17	4638-4643	trial	_
34-18	4644-4645	.	_

35-1	4646-4651	After	_
35-2	4652-4653	a	_
35-3	4654-4664	randomized	_
35-4	4665-4669	time	_
35-5	4670-4678	interval	_
35-6	4679-4680	(	_
35-7	4681-4692	fore-period	_
35-8	4693-4694	)	_
35-9	4695-4702	between	_
35-10	4703-4705	1s	_
35-11	4706-4709	and	_
35-12	4710-4712	5s	_
35-13	4713-4714	,	_
35-14	4715-4718	the	_
35-15	4719-4722	dot	_
35-16	4723-4729	turned	_
35-17	4730-4734	into	_
35-18	4735-4736	a	_
35-19	4737-4743	circle	_
35-20	4744-4745	,	_
35-21	4746-4755	prompting	_
35-22	4756-4759	the	_
35-23	4760-4768	subjects	_
35-24	4769-4771	to	_
35-25	4772-4779	quickly	_
35-26	4780-4785	press	_
35-27	4786-4787	a	_
35-28	4788-4794	button	_
35-29	4795-4796	.	_

36-1	4797-4800	The	_
36-2	4801-4807	circle	_
36-3	4808-4816	vanished	_
36-4	4817-4819	at	_
36-5	4820-4826	button	_
36-6	4827-4832	press	_
36-7	4833-4835	or	_
36-8	4836-4841	after	_
36-9	4842-4844	1s	_
36-10	4845-4848	had	_
36-11	4849-4856	elapsed	_
36-12	4857-4858	,	_
36-13	4859-4868	whichever	_
36-14	4869-4873	came	_
36-15	4874-4879	first	_
36-16	4880-4881	,	_
36-17	4882-4885	and	_
36-18	4886-4889	the	_
36-19	4890-4895	trial	_
36-20	4896-4906	terminated	_
36-21	4907-4908	.	_

37-1	4909-4910	A	_
37-2	4911-4920	premature	_
37-3	4921-4927	button	_
37-4	4928-4933	press	_
37-5	4934-4939	prior	_
37-6	4940-4942	to	_
37-7	4943-4946	the	_
37-8	4947-4957	appearance	_
37-9	4958-4960	of	_
37-10	4961-4964	the	_
37-11	4965-4971	circle	_
37-12	4972-4976	also	_
37-13	4977-4987	terminated	_
37-14	4988-4991	the	_
37-15	4992-4997	trial	_
37-16	4998-4999	.	_

38-1	5000-5005	Three	_
38-2	5006-5014	quarters	_
38-3	5015-5017	of	_
38-4	5018-5021	all	_
38-5	5022-5028	trials	_
38-6	5029-5033	were	_
38-7	5034-5036	go	_
38-8	5037-5043	trials	_
38-9	5044-5045	.	_

39-1	5046-5048	In	_
39-2	5049-5050	a	_
39-3	5051-5055	stop	_
39-4	5056-5061	trial	_
39-5	5062-5063	,	_
39-6	5064-5066	an	_
39-7	5067-5077	additional	_
39-8	5078-5079	“	_
39-9	5080-5081	X	_
39-10	5082-5083	,	_
39-11	5084-5085	”	_
39-12	5086-5089	the	_
39-13	5090-5091	“	_
39-14	5092-5096	stop	_
39-15	5097-5098	”	_
39-16	5099-5105	signal	_
39-17	5106-5107	,	_
39-18	5108-5116	appeared	_
39-19	5117-5122	after	_
39-20	5123-5126	the	_
39-21	5127-5129	go	_
39-22	5130-5136	signal	_
39-23	5137-5138	.	_

40-1	5139-5142	The	_
40-2	5143-5151	subjects	_
40-3	5152-5156	were	_
40-4	5157-5167	instructed	_
40-5	5168-5170	to	_
40-6	5171-5179	withhold	_
40-7	5180-5186	button	_
40-8	5187-5195	pressing	_
40-9	5196-5200	upon	_
40-10	5201-5207	seeing	_
40-11	5208-5211	the	_
40-12	5212-5216	stop	_
40-13	5217-5223	signal	_
40-14	5224-5225	.	_

41-1	5226-5234	Likewise	_
41-2	5235-5236	,	_
41-3	5237-5238	a	_
41-4	5239-5244	trial	_
41-5	5245-5255	terminated	_
41-6	5256-5258	at	_
41-7	5259-5265	button	_
41-8	5266-5271	press	_
41-9	5272-5274	or	_
41-10	5275-5279	when	_
41-11	5280-5282	1s	_
41-12	5283-5286	had	_
41-13	5287-5294	elapsed	_
41-14	5295-5300	since	_
41-15	5301-5304	the	_
41-16	5305-5315	appearance	_
41-17	5316-5318	of	_
41-18	5319-5322	the	_
41-19	5323-5327	stop	_
41-20	5328-5334	signal	_
41-21	5335-5336	.	_

42-1	5337-5340	The	_
42-2	5341-5345	stop	_
42-3	5346-5352	trials	_
42-4	5353-5364	constituted	_
42-5	5365-5368	the	_
42-6	5369-5378	remaining	_
42-7	5379-5382	one	_
42-8	5383-5390	quarter	_
42-9	5391-5393	of	_
42-10	5394-5397	the	_
42-11	5398-5404	trials	_
42-12	5405-5406	.	_

43-1	5407-5412	There	_
43-2	5413-5416	was	_
43-3	5417-5419	an	_
43-4	5420-5440	inter-trial-interval	_
43-5	5441-5443	of	_
43-6	5444-5445	2	_
43-7	5446-5448	s.	_
43-8	5449-5452	The	_
43-9	5453-5457	stop	_
43-10	5458-5464	signal	_
43-11	5465-5470	delay	_
43-12	5471-5472	(	_
43-13	5473-5476	SSD	_
43-14	5477-5478	)	_
43-15	5479-5486	started	_
43-16	5487-5489	at	_
43-17	5490-5493	200	_
43-18	5494-5496	ms	_
43-19	5497-5500	and	_
43-20	5501-5507	varied	_
43-21	5508-5512	from	_
43-22	5513-5516	one	_
43-23	5517-5521	stop	_
43-24	5522-5527	trial	_
43-25	5528-5530	to	_
43-26	5531-5534	the	_
43-27	5535-5539	next	_
43-28	5540-5549	according	_
43-29	5550-5552	to	_
43-30	5553-5554	a	_
43-31	5555-5564	staircase	_
43-32	5565-5574	procedure	_
43-33	5575-5576	,	_
43-34	5577-5587	increasing	_
43-35	5588-5591	and	_
43-36	5592-5602	decreasing	_
43-37	5603-5605	by	_
43-38	5606-5608	64	_
43-39	5609-5611	ms	_
43-40	5612-5616	each	_
43-41	5617-5622	after	_
43-42	5623-5624	a	_
43-43	5625-5635	successful	_
43-44	5636-5639	and	_
43-45	5640-5646	failed	_
43-46	5647-5651	stop	_
43-47	5652-5657	trial	_
43-48	5658-5659	.	_

44-1	5660-5668	Subjects	_
44-2	5669-5673	were	_
44-3	5674-5684	instructed	_
44-4	5685-5687	to	_
44-5	5688-5695	respond	_
44-6	5696-5698	to	_
44-7	5699-5702	the	_
44-8	5703-5705	go	_
44-9	5706-5712	signal	_
44-10	5713-5720	quickly	_
44-11	5721-5726	while	_
44-12	5727-5734	keeping	_
44-13	5735-5737	in	_
44-14	5738-5742	mind	_
44-15	5743-5747	that	_
44-16	5748-5749	a	_
44-17	5750-5754	stop	_
44-18	5755-5761	signal	_
44-19	5762-5767	could	_
44-20	5768-5774	appear	_
44-21	5775-5787	occasionally	_
44-22	5788-5789	.	_

45-1	5790-5794	Each	_
45-2	5795-5802	subject	_
45-3	5803-5812	completed	_
45-4	5813-5817	four	_
45-5	5818-5820	10	_
45-6	5821-5824	min	_
45-7	5825-5829	runs	_
45-8	5830-5832	of	_
45-9	5833-5836	the	_
45-10	5837-5841	task	_
45-11	5842-5847	after	_
45-12	5848-5849	a	_
45-13	5850-5858	practice	_
45-14	5859-5866	session	_
45-15	5867-5874	outside	_
45-16	5875-5878	the	_
45-17	5879-5886	scanner	_
45-18	5887-5888	.	_

46-1	5889-5893	With	_
46-2	5894-5897	the	_
46-3	5898-5907	staircase	_
46-4	5908-5917	procedure	_
46-5	5918-5919	,	_
46-6	5920-5922	we	_
46-7	5923-5934	anticipated	_
46-8	5935-5939	that	_
46-9	5940-5943	the	_
46-10	5944-5952	subjects	_
46-11	5953-5958	would	_
46-12	5959-5966	succeed	_
46-13	5967-5969	in	_
46-14	5970-5981	withholding	_
46-15	5982-5987	their	_
46-16	5988-5996	response	_
46-17	5997-5999	in	_
46-18	6000-6013	approximately	_
46-19	6014-6016	50	_
46-20	6017-6018	%	_
46-21	6019-6021	of	_
46-22	6022-6026	stop	_
46-23	6027-6033	trials	_
46-24	6034-6035	.	_

47-1	6036-6044	Analyses	_
47-2	6045-6047	of	_
47-3	6048-6058	behavioral	_
47-4	6059-6063	data	_
47-5	6064-6066	We	_
47-6	6067-6075	computed	_
47-7	6076-6077	a	_
47-8	6078-6086	critical	_
47-9	6087-6090	SSD	_
47-10	6091-6095	that	_
47-11	6096-6106	represents	_
47-12	6107-6110	the	_
47-13	6111-6115	time	_
47-14	6116-6121	delay	_
47-15	6122-6129	between	_
47-16	6130-6132	go	_
47-17	6133-6136	and	_
47-18	6137-6141	stop	_
47-19	6142-6149	signals	_
47-20	6150-6154	that	_
47-21	6155-6156	a	_
47-22	6157-6164	subject	_
47-23	6165-6170	would	_
47-24	6171-6175	need	_
47-25	6176-6178	to	_
47-26	6179-6186	succeed	_
47-27	6187-6189	in	_
47-28	6190-6192	50	_
47-29	6193-6194	%	_
47-30	6195-6197	of	_
47-31	6198-6201	the	_
47-32	6202-6206	stop	_
47-33	6207-6213	trials	_
47-34	6214-6215	.	_

48-1	6216-6228	Specifically	_
48-2	6229-6230	,	_
48-3	6231-6235	SSDs	_
48-4	6236-6242	across	_
48-5	6243-6249	trials	_
48-6	6250-6254	were	_
48-7	6255-6262	grouped	_
48-8	6263-6267	into	_
48-9	6268-6272	runs	_
48-10	6273-6274	,	_
48-11	6275-6279	with	_
48-12	6280-6284	each	_
48-13	6285-6288	run	_
48-14	6289-6296	defined	_
48-15	6297-6299	as	_
48-16	6300-6301	a	_
48-17	6302-6315	monotonically	_
48-18	6316-6326	increasing	_
48-19	6327-6329	or	_
48-20	6330-6340	decreasing	_
48-21	6341-6347	series	_
48-22	6348-6349	.	_

49-1	6350-6352	We	_
49-2	6353-6360	derived	_
49-3	6361-6362	a	_
49-4	6363-6370	mid-run	_
49-5	6371-6379	estimate	_
49-6	6380-6382	by	_
49-7	6383-6389	taking	_
49-8	6390-6393	the	_
49-9	6394-6400	middle	_
49-10	6401-6404	SSD	_
49-11	6405-6406	(	_
49-12	6407-6409	or	_
49-13	6410-6417	average	_
49-14	6418-6420	of	_
49-15	6421-6424	the	_
49-16	6425-6428	two	_
49-17	6429-6435	middle	_
49-18	6436-6440	SSDs	_
49-19	6441-6445	when	_
49-20	6446-6451	there	_
49-21	6452-6455	was	_
49-22	6456-6458	an	_
49-23	6459-6463	even	_
49-24	6464-6470	number	_
49-25	6471-6473	of	_
49-26	6474-6478	SSDs	_
49-27	6479-6480	)	_
49-28	6481-6483	of	_
49-29	6484-6489	every	_
49-30	6490-6496	second	_
49-31	6497-6500	run	_
49-32	6501-6502	.	_

50-1	6503-6506	The	_
50-2	6507-6515	critical	_
50-3	6516-6519	SSD	_
50-4	6520-6523	was	_
50-5	6524-6532	computed	_
50-6	6533-6535	by	_
50-7	6536-6542	taking	_
50-8	6543-6546	the	_
50-9	6547-6551	mean	_
50-10	6552-6554	of	_
50-11	6555-6558	all	_
50-12	6559-6566	mid-run	_
50-13	6567-6571	SSDs	_
50-14	6572-6573	.	_

51-1	6574-6576	It	_
51-2	6577-6580	was	_
51-3	6581-6589	reported	_
51-4	6590-6594	that	_
51-5	6595-6596	,	_
51-6	6597-6603	except	_
51-7	6604-6607	for	_
51-8	6608-6619	experiments	_
51-9	6620-6624	with	_
51-10	6625-6626	a	_
51-11	6627-6632	small	_
51-12	6633-6639	number	_
51-13	6640-6642	of	_
51-14	6643-6649	trials	_
51-15	6650-6651	(	_
51-16	6652-6656	less	_
51-17	6657-6661	than	_
51-18	6662-6664	30	_
51-19	6665-6666	)	_
51-20	6667-6668	,	_
51-21	6669-6672	the	_
51-22	6673-6680	mid-run	_
51-23	6681-6689	estimate	_
51-24	6690-6693	was	_
51-25	6694-6699	close	_
51-26	6700-6702	to	_
51-27	6703-6706	the	_
51-28	6707-6714	maximum	_
51-29	6715-6725	likelihood	_
51-30	6726-6734	estimate	_
51-31	6735-6737	of	_
51-32	6738-6741	X50	_
51-33	6742-6743	(	_
51-34	6744-6746	50	_
51-35	6747-6748	%	_
51-36	6749-6757	positive	_
51-37	6758-6766	response	_
51-38	6767-6768	;	_
51-39	6769-6773	i.e.	_
51-40	6774-6775	,	_
51-41	6776-6778	50	_
51-42	6779-6780	%	_
51-43	6781-6785	stop	_
51-44	6786-6793	success	_
51-45	6794-6796	or	_
51-46	6797-6799	SS	_
51-47	6800-6802	in	_
51-48	6803-6806	the	_
51-49	6807-6810	SST	_
51-50	6811-6812	,	_
51-51	6813-6814	)	_
51-52	6815-6816	.	_

52-1	6817-6820	The	_
52-2	6821-6825	stop	_
52-3	6826-6832	signal	_
52-4	6833-6841	reaction	_
52-5	6842-6846	time	_
52-6	6847-6848	(	_
52-7	6849-6853	SSRT	_
52-8	6854-6855	)	_
52-9	6856-6859	was	_
52-10	6860-6868	computed	_
52-11	6869-6871	by	_
52-12	6872-6883	subtracting	_
52-13	6884-6887	the	_
52-14	6888-6896	critical	_
52-15	6897-6900	SSD	_
52-16	6901-6905	from	_
52-17	6906-6909	the	_
52-18	6910-6916	median	_
52-19	6917-6919	go	_
52-20	6920-6925	trial	_
52-21	6926-6934	reaction	_
52-22	6935-6939	time	_
52-23	6940-6941	(	_
52-24	6942-6944	RT	_
52-25	6945-6946	)	_
52-26	6947-6948	.	_

53-1	6949-6951	We	_
53-2	6952-6960	computed	_
53-3	6961-6964	the	_
53-4	6965-6976	fore-period	_
53-5	6977-6983	effect	_
53-6	6984-6986	as	_
53-7	6987-6989	an	_
53-8	6990-6995	index	_
53-9	6996-6998	of	_
53-10	6999-7004	motor	_
53-11	7005-7017	preparedness	_
53-12	7018-7024	during	_
53-13	7025-7028	the	_
53-14	7029-7032	SST	_
53-15	7033-7034	.	_

54-1	7035-7042	Briefly	_
54-2	7043-7044	,	_
54-3	7045-7051	longer	_
54-4	7052-7064	fore-periods	_
54-5	7065-7068	are	_
54-6	7069-7079	associated	_
54-7	7080-7084	with	_
54-8	7085-7091	faster	_
54-9	7092-7095	RTs	_
54-10	7096-7097	.	_

55-1	7098-7100	RT	_
55-2	7101-7104	was	_
55-3	7105-7113	compared	_
55-4	7114-7121	between	_
55-5	7122-7124	go	_
55-6	7125-7131	trials	_
55-7	7132-7136	with	_
55-8	7137-7138	a	_
55-9	7139-7150	fore-period	_
55-10	7151-7158	between	_
55-11	7159-7160	3	_
55-12	7161-7164	and	_
55-13	7165-7166	5	_
55-14	7167-7168	s	_
55-15	7169-7172	and	_
55-16	7173-7180	between	_
55-17	7181-7182	1	_
55-18	7183-7186	and	_
55-19	7187-7188	3	_
55-20	7189-7190	s	_
55-21	7191-7192	,	_
55-22	7193-7196	and	_
55-23	7197-7200	the	_
55-24	7201-7207	effect	_
55-25	7208-7212	size	_
55-26	7213-7215	of	_
55-27	7216-7218	RT	_
55-28	7219-7229	difference	_
55-29	7230-7233	was	_
55-30	7234-7241	defined	_
55-31	7242-7244	as	_
55-32	7245-7256	fore-period	_
55-33	7257-7263	effect	_
55-34	7264-7265	.	_

56-1	7266-7268	It	_
56-2	7269-7271	is	_
56-3	7272-7276	also	_
56-4	7277-7282	known	_
56-5	7283-7287	that	_
56-6	7288-7290	in	_
56-7	7291-7292	a	_
56-8	7293-7295	RT	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
56-9	7296-7300	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
56-10	7301-7302	,	_
56-11	7303-7306	the	_
56-12	7307-7309	RT	_
56-13	7310-7312	of	_
56-14	7313-7314	a	_
56-15	7315-7322	correct	_
56-16	7323-7331	response	_
56-17	7332-7334	is	_
56-18	7335-7344	prolonged	_
56-19	7345-7354	following	_
56-20	7355-7357	an	_
56-21	7358-7363	error	_
56-22	7364-7365	,	_
56-23	7366-7374	compared	_
56-24	7375-7379	with	_
56-25	7380-7385	other	_
56-26	7386-7393	correct	_
56-27	7394-7403	responses	_
56-28	7404-7405	,	_
56-29	7406-7409	and	_
56-30	7410-7414	this	_
56-31	7415-7424	prolonged	_
56-32	7425-7427	RT	_
56-33	7428-7430	is	_
56-34	7431-7438	thought	_
56-35	7439-7441	to	_
56-36	7442-7449	reflect	_
56-37	7450-7455	error	_
56-38	7456-7466	monitoring	_
56-39	7467-7468	.	_

57-1	7469-7471	We	_
57-2	7472-7476	thus	_
57-3	7477-7485	computed	_
57-4	7486-7489	the	_
57-5	7490-7492	RT	_
57-6	7493-7503	difference	_
57-7	7504-7511	between	_
57-8	7512-7515	the	_
57-9	7516-7518	go	_
57-10	7519-7525	trials	_
57-11	7526-7530	that	_
57-12	7531-7539	followed	_
57-13	7540-7541	a	_
57-14	7542-7546	stop	_
57-15	7547-7552	error	_
57-16	7553-7554	(	_
57-17	7555-7557	SE	_
57-18	7558-7559	)	_
57-19	7560-7563	and	_
57-20	7564-7569	those	_
57-21	7570-7574	that	_
57-22	7575-7583	followed	_
57-23	7584-7591	another	_
57-24	7592-7594	go	_
57-25	7595-7600	trial	_
57-26	7601-7602	,	_
57-27	7603-7606	and	_
57-28	7607-7613	termed	_
57-29	7614-7617	the	_
57-30	7618-7624	effect	_
57-31	7625-7629	size	_
57-32	7630-7632	of	_
57-33	7633-7637	this	_
57-34	7638-7640	RT	_
57-35	7641-7651	difference	_
57-36	7652-7653	“	_
57-37	7654-7664	post-error	_
57-38	7665-7672	slowing	_
57-39	7673-7674	”	_
57-40	7675-7676	(	_
57-41	7677-7680	PES	_
57-42	7681-7682	)	_
57-43	7683-7684	.	_

58-1	7685-7692	Imaging	_
58-2	7693-7701	protocol	_
58-3	7702-7714	Conventional	_
58-4	7715-7726	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-5	7727-7731	spin	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-6	7732-7736	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-7	7737-7745	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-8	7746-7756	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-9	7757-7763	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-10	7764-7768	were	_
58-11	7769-7777	acquired	_
58-12	7778-7781	for	_
58-13	7782-7787	slice	_
58-14	7788-7800	localization	_
58-15	7801-7806	using	_
58-16	7807-7808	a	_
58-17	7809-7811	3T	_
58-18	7812-7819	scanner	_
58-19	7820-7821	(	_
58-20	7822-7829	Siemens	_
58-21	7830-7834	Trio	_
58-22	7835-7836	)	_
58-23	7837-7838	.	_

59-1	7839-7849	Anatomical	_
59-2	7850-7856	images	_
59-3	7857-7859	of	_
59-4	7860-7863	the	_
59-5	7864-7874	functional	_
59-6	7875-7880	slice	_
59-7	7881-7890	locations	_
59-8	7891-7895	were	_
59-9	7896-7900	next	_
59-10	7901-7909	obtained	_
59-11	7910-7914	with	_
59-12	7915-7924	spin-echo	_
59-13	7925-7932	imaging	_
59-14	7933-7935	in	_
59-15	7936-7939	the	_
59-16	7940-7945	axial	_
59-17	7946-7951	plane	_
59-18	7952-7960	parallel	_
59-19	7961-7963	to	_
59-20	7964-7967	the	_
59-21	7968-7973	AC–PC	_
59-22	7974-7978	line	_
59-23	7979-7983	with	_
59-24	7984-7986	TR	_
59-25	7987-7988	=	_
59-26	7989-7992	300	_
59-27	7993-7995	ms	_
59-28	7996-7997	,	_
59-29	7998-8000	TE	_
59-30	8001-8002	=	_
59-31	8003-8006	2.5	_
59-32	8007-8009	ms	_
59-33	8010-8011	,	_
59-34	8012-8021	bandwidth	_
59-35	8022-8023	=	_
59-36	8024-8027	300	_
59-37	8028-8036	Hz/pixel	_
59-38	8037-8038	,	_
59-39	8039-8043	flip	_
59-40	8044-8049	angle	_
59-41	8050-8051	=	_
59-42	8052-8055	60°	_
59-43	8056-8057	,	_
59-44	8058-8063	field	_
59-45	8064-8066	of	_
59-46	8067-8071	view	_
59-47	8072-8073	=	_
59-48	8074-8077	220	_
59-49	8078-8080	mm	_
59-50	8081-8082	×	_
59-51	8083-8086	220	_
59-52	8087-8089	mm	_
59-53	8090-8091	,	_
59-54	8092-8098	matrix	_
59-55	8099-8100	=	_
59-56	8101-8104	256	_
59-57	8105-8106	×	_
59-58	8107-8110	256	_
59-59	8111-8112	,	_
59-60	8113-8115	32	_
59-61	8116-8122	slices	_
59-62	8123-8127	with	_
59-63	8128-8133	slice	_
59-64	8134-8143	thickness	_
59-65	8144-8145	=	_
59-66	8146-8147	4	_
59-67	8148-8150	mm	_
59-68	8151-8154	and	_
59-69	8155-8157	no	_
59-70	8158-8161	gap	_
59-71	8162-8163	.	_

60-1	8164-8174	Functional	_
60-2	8175-8176	,	_
60-3	8177-8182	blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-4	8183-8189	oxygen	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-5	8190-8205	level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-6	8206-8207	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-7	8208-8212	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-8	8213-8214	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
60-9	8215-8222	signals	_
60-10	8223-8227	were	_
60-11	8228-8232	then	_
60-12	8233-8241	acquired	_
60-13	8242-8246	with	_
60-14	8247-8248	a	_
60-15	8249-8260	single-shot	_
60-16	8261-8269	gradient	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-17	8270-8274	echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-18	8275-8279	echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-19	8280-8286	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-20	8287-8294	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-21	8295-8296	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-22	8297-8300	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-23	8301-8302	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-24	8303-8311	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
60-25	8312-8313	.	_

61-1	8314-8324	Thirty-two	_
61-2	8325-8330	axial	_
61-3	8331-8337	slices	_
61-4	8338-8346	parallel	_
61-5	8347-8349	to	_
61-6	8350-8353	the	_
61-7	8354-8359	AC–PC	_
61-8	8360-8364	line	_
61-9	8365-8373	covering	_
61-10	8374-8377	the	_
61-11	8378-8383	whole	_
61-12	8384-8389	brain	_
61-13	8390-8394	were	_
61-14	8395-8403	acquired	_
61-15	8404-8408	with	_
61-16	8409-8411	TR	_
61-17	8412-8413	=	_
61-18	8414-8418	2000	_
61-19	8419-8421	ms	_
61-20	8422-8423	,	_
61-21	8424-8426	TE	_
61-22	8427-8428	=	_
61-23	8429-8433	25ms	_
61-24	8434-8435	,	_
61-25	8436-8445	bandwidth	_
61-26	8446-8447	=	_
61-27	8448-8452	2004	_
61-28	8453-8461	Hz/pixel	_
61-29	8462-8463	,	_
61-30	8464-8468	flip	_
61-31	8469-8474	angle	_
61-32	8475-8476	=	_
61-33	8477-8480	85°	_
61-34	8481-8482	,	_
61-35	8483-8488	field	_
61-36	8489-8491	of	_
61-37	8492-8496	view	_
61-38	8497-8498	=	_
61-39	8499-8502	220	_
61-40	8503-8505	mm	_
61-41	8506-8507	×	_
61-42	8508-8513	220mm	_
61-43	8514-8515	,	_
61-44	8516-8522	matrix	_
61-45	8523-8524	=	_
61-46	8525-8527	64	_
61-47	8528-8529	×	_
61-48	8530-8532	64	_
61-49	8533-8534	,	_
61-50	8535-8537	32	_
61-51	8538-8544	slices	_
61-52	8545-8549	with	_
61-53	8550-8555	slice	_
61-54	8556-8565	thickness	_
61-55	8566-8567	=	_
61-56	8568-8569	4	_
61-57	8570-8572	mm	_
61-58	8573-8576	and	_
61-59	8577-8579	no	_
61-60	8580-8583	gap	_
61-61	8584-8585	.	_

62-1	8586-8593	Spatial	_
62-2	8594-8607	preprocessing	_
62-3	8608-8612	Data	_
62-4	8613-8617	were	_
62-5	8618-8626	analyzed	_
62-6	8627-8631	with	_
62-7	8632-8643	Statistical	_
62-8	8644-8654	Parametric	_
62-9	8655-8662	Mapping	_
62-10	8663-8664	(	_
62-11	8665-8669	SPM8	_
62-12	8670-8671	,	_
62-13	8672-8680	Wellcome	_
62-14	8681-8691	Department	_
62-15	8692-8694	of	_
62-16	8695-8702	Imaging	_
62-17	8703-8715	Neuroscience	_
62-18	8716-8717	,	_
62-19	8718-8728	University	_
62-20	8729-8736	College	_
62-21	8737-8743	London	_
62-22	8744-8745	,	_
62-23	8746-8750	U.K.	_
62-24	8751-8752	)	_
62-25	8753-8754	.	_

63-1	8755-8761	Images	_
63-2	8762-8766	from	_
63-3	8767-8770	the	_
63-4	8771-8776	first	_
63-5	8777-8781	five	_
63-6	8782-8785	TRs	_
63-7	8786-8788	at	_
63-8	8789-8792	the	_
63-9	8793-8802	beginning	_
63-10	8803-8805	of	_
63-11	8806-8810	each	_
63-12	8811-8816	trial	_
63-13	8817-8821	were	_
63-14	8822-8831	discarded	_
63-15	8832-8834	to	_
63-16	8835-8841	enable	_
63-17	8842-8845	the	_
63-18	8846-8852	signal	_
63-19	8853-8855	to	_
63-20	8856-8863	achieve	_
63-21	8864-8876	steady-state	_
63-22	8877-8888	equilibrium	_
63-23	8889-8896	between	_
63-24	8897-8899	RF	_
63-25	8900-8907	pulsing	_
63-26	8908-8911	and	_
63-27	8912-8922	relaxation	_
63-28	8923-8924	.	_

64-1	8925-8933	Standard	_
64-2	8934-8939	image	_
64-3	8940-8953	preprocessing	_
64-4	8954-8957	was	_
64-5	8958-8967	performed	_
64-6	8968-8969	.	_

65-1	8970-8976	Images	_
65-2	8977-8979	of	_
65-3	8980-8984	each	_
65-4	8985-8995	individual	_
65-5	8996-9003	subject	_
65-6	9004-9008	were	_
65-7	9009-9014	first	_
65-8	9015-9024	realigned	_
65-9	9025-9026	(	_
65-10	9027-9033	motion	_
65-11	9034-9043	corrected	_
65-12	9044-9045	)	_
65-13	9046-9049	and	_
65-14	9050-9059	corrected	_
65-15	9060-9063	for	_
65-16	9064-9069	slice	_
65-17	9070-9076	timing	_
65-18	9077-9078	.	_

66-1	9079-9080	A	_
66-2	9081-9085	mean	_
66-3	9086-9096	functional	_
66-4	9097-9102	image	_
66-5	9103-9109	volume	_
66-6	9110-9113	was	_
66-7	9114-9125	constructed	_
66-8	9126-9129	for	_
66-9	9130-9134	each	_
66-10	9135-9142	subject	_
66-11	9143-9146	per	_
66-12	9147-9150	run	_
66-13	9151-9155	from	_
66-14	9156-9159	the	_
66-15	9160-9169	realigned	_
66-16	9170-9175	image	_
66-17	9176-9183	volumes	_
66-18	9184-9185	.	_

67-1	9186-9191	These	_
67-2	9192-9196	mean	_
67-3	9197-9203	images	_
67-4	9204-9208	were	_
67-5	9209-9222	co-registered	_
67-6	9223-9227	with	_
67-7	9228-9231	the	_
67-8	9232-9247	high-resolution	_
67-9	9248-9258	structural	_
67-10	9259-9264	image	_
67-11	9265-9268	and	_
67-12	9269-9273	then	_
67-13	9274-9283	segmented	_
67-14	9284-9287	for	_
67-15	9288-9301	normalization	_
67-16	9302-9306	with	_
67-17	9307-9313	affine	_
67-18	9314-9326	registration	_
67-19	9327-9335	followed	_
67-20	9336-9338	by	_
67-21	9339-9348	nonlinear	_
67-22	9349-9363	transformation	_
67-23	9364-9365	.	_

68-1	9366-9369	The	_
68-2	9370-9383	normalization	_
68-3	9384-9394	parameters	_
68-4	9395-9405	determined	_
68-5	9406-9409	for	_
68-6	9410-9413	the	_
68-7	9414-9423	structure	_
68-8	9424-9430	volume	_
68-9	9431-9435	were	_
68-10	9436-9440	then	_
68-11	9441-9448	applied	_
68-12	9449-9451	to	_
68-13	9452-9455	the	_
68-14	9456-9469	corresponding	_
68-15	9470-9480	functional	_
68-16	9481-9486	image	_
68-17	9487-9494	volumes	_
68-18	9495-9498	for	_
68-19	9499-9503	each	_
68-20	9504-9511	subject	_
68-21	9512-9513	.	_

69-1	9514-9521	Finally	_
69-2	9522-9523	,	_
69-3	9524-9527	the	_
69-4	9528-9534	images	_
69-5	9535-9539	were	_
69-6	9540-9548	smoothed	_
69-7	9549-9553	with	_
69-8	9554-9555	a	_
69-9	9556-9564	Gaussian	_
69-10	9565-9571	kernel	_
69-11	9572-9574	of	_
69-12	9575-9576	8	_
69-13	9577-9579	mm	_
69-14	9580-9582	at	_
69-15	9583-9587	Full	_
69-16	9588-9593	Width	_
69-17	9594-9596	at	_
69-18	9597-9601	Half	_
69-19	9602-9609	Maximum	_
69-20	9610-9611	.	_

70-1	9612-9623	Independent	_
70-2	9624-9633	component	_
70-3	9634-9642	analysis	_
70-4	9643-9655	Preprocessed	_
70-5	9656-9660	time	_
70-6	9661-9667	series	_
70-7	9668-9672	were	_
70-8	9673-9681	analyzed	_
70-9	9682-9686	with	_
70-10	9687-9688	a	_
70-11	9689-9694	group	_
70-12	9695-9698	ICA	_
70-13	9699-9708	algorithm	_
70-14	9709-9710	(	_
70-15	9711-9715	GIFT	_
70-16	9716-9717	,	_
70-17	9718-9722	http	_
70-18	9723-9724	:	_
70-19	9725-9749	//icatb.sourceforge.net/	_
70-20	9750-9751	,	_
70-21	9752-9759	version	_
70-22	9760-9764	1.3i	_
70-23	9765-9766	)	_
70-24	9767-9769	to	_
70-25	9770-9778	identify	_
70-26	9779-9788	spatially	_
70-27	9789-9800	independent	_
70-28	9801-9804	and	_
70-29	9805-9815	temporally	_
70-30	9816-9824	coherent	_
70-31	9825-9833	networks	_
70-32	9834-9835	.	_

71-1	9836-9839	ICA	_
71-2	9840-9850	identifies	_
71-3	9851-9859	distinct	_
71-4	9860-9866	groups	_
71-5	9867-9869	of	_
71-6	9870-9875	brain	_
71-7	9876-9883	regions	_
71-8	9884-9888	with	_
71-9	9889-9892	the	_
71-10	9893-9897	same	_
71-11	9898-9906	temporal	_
71-12	9907-9914	pattern	_
71-13	9915-9917	of	_
71-14	9918-9929	hemodynamic	_
71-15	9930-9936	signal	_
71-16	9937-9943	change	_
71-17	9944-9945	.	_

72-1	9946-9949	The	_
72-2	9950-9954	data	_
72-3	9955-9957	of	_
72-4	9958-9960	CD	_
72-5	9961-9962	(	_
72-6	9963-9964	n	_
72-7	9965-9966	=	_
72-8	9967-9970	100	_
72-9	9971-9972	)	_
72-10	9973-9976	and	_
72-11	9977-9979	HC	_
72-12	9980-9981	(	_
72-13	9982-9983	n	_
72-14	9984-9985	=	_
72-15	9986-9989	100	_
72-16	9990-9991	)	_
72-17	9992-10003	individuals	_
72-18	10004-10008	were	_
72-19	10009-10016	reduced	_
72-20	10017-10024	through	_
72-21	10025-10034	principal	_
72-22	10035-10044	component	_
72-23	10045-10053	analysis	_
72-24	10054-10057	and	_
72-25	10058-10067	separated	_
72-26	10068-10072	into	_
72-27	10073-10075	30	_
72-28	10076-10085	maximally	_
72-29	10086-10097	independent	_
72-30	10098-10108	components	_
72-31	10109-10110	(	_
72-32	10111-10114	ICs	_
72-33	10115-10116	)	_
72-34	10117-10121	with	_
72-35	10122-10124	an	_
72-36	10125-10132	infomax	_
72-37	10133-10142	algorithm	_
72-38	10143-10144	.	_

73-1	10145-10148	The	_
73-2	10149-10163	dimensionality	_
73-3	10164-10167	was	_
73-4	10168-10178	determined	_
73-5	10179-10181	by	_
73-6	10182-10185	the	_
73-7	10186-10194	modified	_
73-8	10195-10202	minimal	_
73-9	10203-10214	description	_
73-10	10215-10221	length	_
73-11	10222-10223	(	_
73-12	10224-10227	MDL	_
73-13	10228-10229	)	_
73-14	10230-10238	criteria	_
73-15	10239-10241	as	_
73-16	10242-10253	implemented	_
73-17	10254-10256	in	_
73-18	10257-10261	GIFT	_
73-19	10262-10265	and	_
73-20	10266-10274	averaged	_
73-21	10275-10281	across	_
73-22	10282-10290	subjects	_
73-23	10291-10292	.	_

74-1	10293-10294	A	_
74-2	10295-10299	time	_
74-3	10300-10306	course	_
74-4	10307-10310	for	_
74-5	10311-10315	each	_
74-6	10316-10318	IC	_
74-7	10319-10322	and	_
74-8	10323-10326	its	_
74-9	10327-10340	corresponding	_
74-10	10341-10348	spatial	_
74-11	10349-10352	map	_
74-12	10353-10356	was	_
74-13	10357-10365	obtained	_
74-14	10366-10367	.	_

75-1	10368-10372	This	_
75-2	10373-10381	analysis	_
75-3	10382-10385	was	_
75-4	10386-10394	repeated	_
75-5	10395-10397	20	_
75-6	10398-10403	times	_
75-7	10404-10408	with	_
75-8	10409-10415	ICASSO	_
75-9	10416-10418	to	_
75-10	10419-10425	assess	_
75-11	10426-10429	the	_
75-12	10430-10443	repeatability	_
75-13	10444-10446	of	_
75-14	10447-10450	ICs	_
75-15	10451-10452	.	_

76-1	10453-10460	Finally	_
76-2	10461-10462	,	_
76-3	10463-10472	component	_
76-4	10473-10477	time	_
76-5	10478-10485	courses	_
76-6	10486-10489	and	_
76-7	10490-10497	spatial	_
76-8	10498-10502	maps	_
76-9	10503-10504	,	_
76-10	10505-10510	which	_
76-11	10511-10519	captured	_
76-12	10520-10530	individual	_
76-13	10531-10542	differences	_
76-14	10543-10545	in	_
76-15	10546-10549	the	_
76-16	10550-10560	expression	_
76-17	10561-10563	of	_
76-18	10564-10567	the	_
76-19	10568-10579	ICA-derived	_
76-20	10580-10589	component	_
76-21	10590-10591	,	_
76-22	10592-10596	were	_
76-23	10597-10601	back	_
76-24	10602-10615	reconstructed	_
76-25	10616-10619	for	_
76-26	10620-10624	each	_
76-27	10625-10636	participant	_
76-28	10637-10638	.	_

77-1	10639-10648	Following	_
77-2	10649-10652	our	_
77-3	10653-10661	previous	_
77-4	10662-10667	study	_
77-5	10668-10669	,	_
77-6	10670-10673	six	_
77-7	10674-10677	ICs	_
77-8	10678-10679	,	_
77-9	10680-10689	including	_
77-10	10690-10691	a	_
77-11	10692-10697	motor	_
77-12	10698-10706	cortical	_
77-13	10707-10714	network	_
77-14	10715-10718	for	_
77-15	10719-10724	motor	_
77-16	10725-10736	preparation	_
77-17	10737-10740	and	_
77-18	10741-10750	execution	_
77-19	10751-10752	,	_
77-20	10753-10754	a	_
77-21	10755-10760	right	_
77-22	10761-10776	fronto-parietal	_
77-23	10777-10784	network	_
77-24	10785-10788	for	_
77-25	10789-10800	attentional	_
77-26	10801-10811	monitoring	_
77-27	10812-10813	,	_
77-28	10814-10815	a	_
77-29	10816-10820	left	_
77-30	10821-10836	fronto-parietal	_
77-31	10837-10844	network	_
77-32	10845-10848	for	_
77-33	10849-10857	response	_
77-34	10858-10868	inhibition	_
77-35	10869-10870	,	_
77-36	10871-10872	a	_
77-37	10873-10880	midline	_
77-38	10881-10900	cortico-subcortical	_
77-39	10901-10908	network	_
77-40	10909-10912	for	_
77-41	10913-10918	error	_
77-42	10919-10929	processing	_
77-43	10930-10931	,	_
77-44	10932-10933	a	_
77-45	10934-10950	cuneus-precuneus	_
77-46	10951-10958	network	_
77-47	10959-10962	for	_
77-48	10963-10973	behavioral	_
77-49	10974-10984	engagement	_
77-50	10985-10986	,	_
77-51	10987-10990	and	_
77-52	10991-10992	a	_
77-53	10993-11005	default-mode	_
77-54	11006-11013	network	_
77-55	11014-11015	(	_
77-56	11016-11019	DMN	_
77-57	11020-11021	)	_
77-58	11022-11025	for	_
77-59	11026-11042	self-referential	_
77-60	11043-11053	processing	_
77-61	11054-11055	,	_
77-62	11056-11060	were	_
77-63	11061-11069	included	_
77-64	11070-11073	for	_
77-65	11074-11081	further	_
77-66	11082-11090	analyses	_
77-67	11091-11092	.	_

78-1	11093-11095	We	_
78-2	11096-11106	normalized	_
78-3	11107-11125	back-reconstructed	_
78-4	11126-11133	spatial	_
78-5	11134-11138	maps	_
78-6	11139-11141	of	_
78-7	11142-11146	each	_
78-8	11147-11149	IC	_
78-9	11150-11154	into	_
78-10	11155-11163	z-scores	_
78-11	11164-11167	and	_
78-12	11168-11176	averaged	_
78-13	11177-11181	them	_
78-14	11182-11188	across	_
78-15	11189-11193	runs	_
78-16	11194-11197	for	_
78-17	11198-11202	each	_
78-18	11203-11214	participant	_
78-19	11215-11216	.	_

79-1	11217-11218	A	_
79-2	11219-11229	one-sample	_
79-3	11230-11231	t	_
79-4	11232-11236	test	_
79-5	11237-11240	was	_
79-6	11241-11248	applied	_
79-7	11249-11251	to	_
79-8	11252-11255	the	_
79-9	11256-11257	“	_
79-10	11258-11259	z	_
79-11	11260-11264	maps	_
79-12	11265-11266	”	_
79-13	11267-11273	across	_
79-14	11274-11277	all	_
79-15	11278-11290	participants	_
79-16	11291-11293	to	_
79-17	11294-11300	define	_
79-18	11301-11312	significant	_
79-19	11313-11318	brain	_
79-20	11319-11326	regions	_
79-21	11327-11337	associated	_
79-22	11338-11342	with	_
79-23	11343-11347	each	_
79-24	11348-11350	IC	_
79-25	11351-11352	.	_

80-1	11353-11365	Multivariate	_
80-2	11366-11373	pattern	_
80-3	11374-11382	analysis	_
80-4	11383-11384	(	_
80-5	11385-11389	MVPA	_
80-6	11390-11391	)	_
80-7	11392-11394	of	_
80-8	11395-11398	the	_
80-9	11399-11407	thalamic	_
80-10	11408-11420	connectivity	_
80-11	11421-11424	Fig	_
80-12	11425-11426	.	_

81-1	11427-11428	1	_
81-2	11429-11440	illustrates	_
81-3	11441-11444	the	_
81-4	11445-11453	analyses	_
81-5	11454-11466	step-by-step	_
81-6	11467-11471	with	_
81-7	11472-11479	details	_
81-8	11480-11489	described	_
81-9	11490-11492	as	_
81-10	11493-11500	follows	_
81-11	11501-11502	.	_

82-1	11503-11504	A	_
82-2	11505-11517	multivariate	_
82-3	11518-11525	pattern	_
82-4	11526-11536	classifier	_
82-5	11537-11540	was	_
82-6	11541-11548	trained	_
82-7	11549-11551	to	_
82-8	11552-11560	identify	_
82-9	11561-11563	CD	_
82-10	11564-11568	from	_
82-11	11569-11571	HC	_
82-12	11572-11573	,	_
82-13	11574-11582	followed	_
82-14	11583-11585	by	_
82-15	11586-11602	cross-validation	_
82-16	11603-11608	using	_
82-17	11609-11610	“	_
82-18	11611-11624	leave-one-out	_
82-19	11625-11626	”	_
82-20	11627-11628	.	_

83-1	11629-11636	Briefly	_
83-2	11637-11638	,	_
83-3	11639-11642	one	_
83-4	11643-11645	CD	_
83-5	11646-11648	or	_
83-6	11649-11651	HC	_
83-7	11652-11655	was	_
83-8	11656-11660	left	_
83-9	11661-11664	out	_
83-10	11665-11667	as	_
83-11	11668-11675	testing	_
83-12	11676-11680	data	_
83-13	11681-11686	while	_
83-14	11687-11690	the	_
83-15	11691-11700	remaining	_
83-16	11701-11709	subjects	_
83-17	11710-11714	were	_
83-18	11715-11719	used	_
83-19	11720-11722	to	_
83-20	11723-11728	train	_
83-21	11729-11732	the	_
83-22	11733-11743	classifier	_
83-23	11744-11745	.	_

84-1	11746-11750	This	_
84-2	11751-11760	procedure	_
84-3	11761-11764	was	_
84-4	11765-11773	repeated	_
84-5	11774-11779	until	_
84-6	11780-11784	each	_
84-7	11785-11787	of	_
84-8	11788-11791	the	_
84-9	11792-11795	100	_
84-10	11796-11798	CD	_
84-11	11799-11802	and	_
84-12	11803-11806	100	_
84-13	11807-11809	HC	_
84-14	11810-11813	was	_
84-15	11814-11822	selected	_
84-16	11823-11827	once	_
84-17	11828-11830	as	_
84-18	11831-11834	the	_
84-19	11835-11845	validation	_
84-20	11846-11850	data	_
84-21	11851-11852	.	_

85-1	11853-11854	A	_
85-2	11855-11863	thalamus	_
85-3	11864-11868	mask	_
85-4	11869-11870	(	_
85-5	11871-11874	698	_
85-6	11875-11881	voxels	_
85-7	11882-11883	)	_
85-8	11884-11887	was	_
85-9	11888-11896	obtained	_
85-10	11897-11901	from	_
85-11	11902-11905	the	_
85-12	11906-11915	Automated	_
85-13	11916-11926	Anatomical	_
85-14	11927-11935	Labeling	_
85-15	11936-11941	atlas	_
85-16	11942-11943	.	_

86-1	11944-11947	For	_
86-2	11948-11952	each	_
86-3	11953-11964	participant	_
86-4	11965-11966	,	_
86-5	11967-11969	we	_
86-6	11970-11979	extracted	_
86-7	11980-11981	z	_
86-8	11982-11988	values	_
86-9	11989-11991	of	_
86-10	11992-12000	thalamic	_
86-11	12001-12007	voxels	_
86-12	12008-12011	for	_
86-13	12012-12015	all	_
86-14	12016-12017	6	_
86-15	12018-12021	ICs	_
86-16	12022-12024	as	_
86-17	12025-12026	a	_
86-18	12027-12041	classification	_
86-19	12042-12049	feature	_
86-20	12050-12056	vector	_
86-21	12057-12058	,	_
86-22	12059-12068	resulting	_
86-23	12069-12071	in	_
86-24	12072-12073	a	_
86-25	12074-12079	total	_
86-26	12080-12082	of	_
86-27	12083-12086	698	_
86-28	12087-12088	×	_
86-29	12089-12090	6	_
86-30	12091-12092	=	_
86-31	12093-12097	4188	_
86-32	12098-12106	features	_
86-33	12107-12108	.	_

87-1	12109-12112	The	_
87-2	12113-12120	feature	_
87-3	12121-12126	space	_
87-4	12127-12130	was	_
87-5	12131-12138	refined	_
87-6	12139-12141	by	_
87-7	12142-12151	retaining	_
87-8	12152-12155	the	_
87-9	12156-12160	most	_
87-10	12161-12175	discriminating	_
87-11	12176-12184	features	_
87-12	12185-12186	,	_
87-13	12187-12189	as	_
87-14	12190-12198	assessed	_
87-15	12199-12201	by	_
87-16	12202-12214	feature-wise	_
87-17	12215-12225	two-sample	_
87-18	12226-12227	t	_
87-19	12228-12233	tests	_
87-20	12234-12236	of	_
87-21	12237-12239	CD	_
87-22	12240-12246	versus	_
87-23	12247-12249	HC	_
87-24	12250-12255	using	_
87-25	12256-12264	training	_
87-26	12265-12269	data	_
87-27	12270-12274	only	_
87-28	12275-12276	;	_
87-29	12277-12285	features	_
87-30	12286-12290	that	_
87-31	12291-12299	differed	_
87-32	12300-12307	between	_
87-33	12308-12310	CD	_
87-34	12311-12314	and	_
87-35	12315-12317	HC	_
87-36	12318-12320	at	_
87-37	12321-12322	p	_
87-38	12323-12324	<	_
87-39	12325-12329	0.05	_
87-40	12330-12331	,	_
87-41	12332-12343	uncorrected	_
87-42	12344-12348	were	_
87-43	12349-12357	included	_
87-44	12358-12360	in	_
87-45	12361-12364	the	_
87-46	12365-12372	feature	_
87-47	12373-12376	set	_
87-48	12377-12380	for	_
87-49	12381-12395	classification	_
87-50	12396-12397	.	_

88-1	12398-12403	Since	_
88-2	12404-12405	a	_
88-3	12406-12414	distinct	_
88-4	12415-12418	set	_
88-5	12419-12421	of	_
88-6	12422-12430	features	_
88-7	12431-12435	were	_
88-8	12436-12444	selected	_
88-9	12445-12449	from	_
88-10	12450-12454	each	_
88-11	12455-12458	set	_
88-12	12459-12461	of	_
88-13	12462-12470	training	_
88-14	12471-12475	data	_
88-15	12476-12477	,	_
88-16	12478-12481	the	_
88-17	12482-12487	final	_
88-18	12488-12495	feature	_
88-19	12496-12499	set	_
88-20	12500-12508	differed	_
88-21	12509-12517	slightly	_
88-22	12518-12522	from	_
88-23	12523-12532	iteration	_
88-24	12533-12535	to	_
88-25	12536-12545	iteration	_
88-26	12546-12547	.	_

89-1	12548-12550	We	_
89-2	12551-12555	thus	_
89-3	12556-12560	used	_
89-4	12561-12564	the	_
89-5	12565-12574	frequency	_
89-6	12575-12579	with	_
89-7	12580-12585	which	_
89-8	12586-12590	each	_
89-9	12591-12598	feature	_
89-10	12599-12602	was	_
89-11	12603-12611	included	_
89-12	12612-12614	in	_
89-13	12615-12618	the	_
89-14	12619-12633	classification	_
89-15	12634-12638	sets	_
89-16	12639-12645	across	_
89-17	12646-12649	all	_
89-18	12650-12660	iterations	_
89-19	12661-12663	to	_
89-20	12664-12673	represent	_
89-21	12674-12677	its	_
89-22	12678-12692	discriminative	_
89-23	12693-12698	power	_
89-24	12699-12700	.	_

90-1	12701-12703	We	_
90-2	12704-12712	employed	_
90-3	12713-12714	a	_
90-4	12715-12722	support	_
90-5	12723-12729	vector	_
90-6	12730-12737	machine	_
90-7	12738-12739	(	_
90-8	12740-12743	SVM	_
90-9	12744-12745	)	_
90-10	12746-12756	classifier	_
90-11	12757-12761	with	_
90-12	12762-12763	a	_
90-13	12764-12770	linear	_
90-14	12771-12777	kernel	_
90-15	12778-12786	function	_
90-16	12787-12790	for	_
90-17	12791-12805	classification	_
90-18	12806-12807	,	_
90-19	12808-12810	as	_
90-20	12811-12813	in	_
90-21	12814-12822	previous	_
90-22	12823-12827	work	_
90-23	12828-12830	of	_
90-24	12831-12835	MVPA	_
90-25	12836-12837	.	_

91-1	12838-12844	Linear	_
91-2	12845-12848	SVM	_
91-3	12849-12854	helps	_
91-4	12855-12857	to	_
91-5	12858-12863	weigh	_
91-6	12864-12868	down	_
91-7	12869-12872	the	_
91-8	12873-12879	effect	_
91-9	12880-12882	of	_
91-10	12883-12888	noisy	_
91-11	12889-12897	features	_
91-12	12898-12902	that	_
91-13	12903-12906	are	_
91-14	12907-12913	highly	_
91-15	12914-12924	correlated	_
91-16	12925-12926	.	_

92-1	12927-12936	According	_
92-2	12937-12939	to	_
92-3	12940-12943	the	_
92-4	12944-12951	results	_
92-5	12952-12954	of	_
92-6	12955-12971	cross-validation	_
92-7	12972-12973	,	_
92-8	12974-12976	we	_
92-9	12977-12981	used	_
92-10	12982-12985	the	_
92-11	12986-13000	generalization	_
92-12	13001-13005	rate	_
92-13	13006-13007	,	_
92-14	13008-13019	sensitivity	_
92-15	13020-13023	and	_
92-16	13024-13035	specificity	_
92-17	13036-13038	to	_
92-18	13039-13047	quantify	_
92-19	13048-13051	the	_
92-20	13052-13063	performance	_
92-21	13064-13066	of	_
92-22	13067-13070	our	_
92-23	13071-13081	classifier	_
92-24	13082-13083	.	_

93-1	13084-13087	The	_
93-2	13088-13102	generalization	_
93-3	13103-13107	rate	_
93-4	13108-13118	represents	_
93-5	13119-13122	the	_
93-6	13123-13130	overall	_
93-7	13131-13141	prediction	_
93-8	13142-13146	rate	_
93-9	13147-13149	of	_
93-10	13150-13152	CD	_
93-11	13153-13156	and	_
93-12	13157-13159	HC	_
93-13	13160-13168	combined	_
93-14	13169-13170	,	_
93-15	13171-13178	whereas	_
93-16	13179-13182	the	_
93-17	13183-13194	sensitivity	_
93-18	13195-13198	and	_
93-19	13199-13210	specificity	_
93-20	13211-13215	each	_
93-21	13216-13229	characterizes	_
93-22	13230-13233	the	_
93-23	13234-13244	prediction	_
93-24	13245-13250	rates	_
93-25	13251-13253	of	_
93-26	13254-13256	CD	_
93-27	13257-13260	and	_
93-28	13261-13263	HC	_
93-29	13264-13265	.	_

94-1	13266-13268	We	_
94-2	13269-13273	used	_
94-3	13274-13285	permutation	_
94-4	13286-13291	tests	_
94-5	13292-13294	to	_
94-6	13295-13302	examine	_
94-7	13303-13306	the	_
94-8	13307-13318	statistical	_
94-9	13319-13331	significance	_
94-10	13332-13334	of	_
94-11	13335-13338	the	_
94-12	13339-13347	observed	_
94-13	13348-13362	classification	_
94-14	13363-13371	accuracy	_
94-15	13372-13373	.	_

95-1	13374-13376	In	_
95-2	13377-13381	each	_
95-3	13382-13393	permutation	_
95-4	13394-13395	,	_
95-5	13396-13399	the	_
95-6	13400-13405	group	_
95-7	13406-13411	label	_
95-8	13412-13414	of	_
95-9	13415-13418	the	_
95-10	13419-13427	training	_
95-11	13428-13432	data	_
95-12	13433-13437	were	_
95-13	13438-13446	randomly	_
95-14	13447-13455	permuted	_
95-15	13456-13461	prior	_
95-16	13462-13464	to	_
95-17	13465-13473	training	_
95-18	13474-13477	and	_
95-19	13478-13479	a	_
95-20	13480-13494	generalization	_
95-21	13495-13499	rate	_
95-22	13500-13503	was	_
95-23	13504-13512	computed	_
95-24	13513-13514	.	_

96-1	13515-13518	The	_
96-2	13519-13530	permutation	_
96-3	13531-13534	was	_
96-4	13535-13543	repeated	_
96-5	13544-13548	1000	_
96-6	13549-13554	times	_
96-7	13555-13557	to	_
96-8	13558-13564	obtain	_
96-9	13565-13566	a	_
96-10	13567-13579	distribution	_
96-11	13580-13582	of	_
96-12	13583-13597	generalization	_
96-13	13598-13603	rates	_
96-14	13604-13605	,	_
96-15	13606-13613	against	_
96-16	13614-13619	which	_
96-17	13620-13623	the	_
96-18	13624-13632	accuracy	_
96-19	13633-13635	in	_
96-20	13636-13650	classification	_
96-21	13651-13653	of	_
96-22	13654-13657	the	_
96-23	13658-13669	veridically	_
96-24	13670-13677	labeled	_
96-25	13678-13682	data	_
96-26	13683-13686	was	_
96-27	13687-13693	tested	_
96-28	13694-13695	.	_

97-1	13696-13698	In	_
97-2	13699-13707	addition	_
97-3	13708-13710	to	_
97-4	13711-13714	the	_
97-5	13715-13723	thalamus	_
97-6	13724-13725	,	_
97-7	13726-13728	we	_
97-8	13729-13737	examined	_
97-9	13738-13743	other	_
97-10	13744-13747	AAL	_
97-11	13748-13753	masks	_
97-12	13754-13758	with	_
97-13	13759-13760	a	_
97-14	13761-13768	similar	_
97-15	13769-13775	volume	_
97-16	13776-13779	for	_
97-17	13780-13790	comparison	_
97-18	13791-13792	.	_

98-1	13793-13798	These	_
98-2	13799-13806	regions	_
98-3	13807-13815	included	_
98-4	13816-13819	the	_
98-5	13820-13831	paracentral	_
98-6	13832-13838	lobule	_
98-7	13839-13840	(	_
98-8	13841-13844	695	_
98-9	13845-13851	voxels	_
98-10	13852-13853	)	_
98-11	13854-13855	,	_
98-12	13856-13859	the	_
98-13	13860-13867	caudate	_
98-14	13868-13869	(	_
98-15	13870-13873	658	_
98-16	13874-13880	voxels	_
98-17	13881-13882	)	_
98-18	13883-13884	,	_
98-19	13885-13891	middle	_
98-20	13892-13896	part	_
98-21	13897-13899	of	_
98-22	13900-13907	orbital	_
98-23	13908-13915	frontal	_
98-24	13916-13921	gyrus	_
98-25	13922-13923	(	_
98-26	13924-13927	694	_
98-27	13928-13934	voxels	_
98-28	13935-13936	)	_
98-29	13937-13938	,	_
98-30	13939-13954	parahippocampal	_
98-31	13955-13960	gyrus	_
98-32	13961-13962	(	_
98-33	13963-13966	728	_
98-34	13967-13973	voxels	_
98-35	13974-13975	)	_
98-36	13976-13977	,	_
98-37	13978-13981	and	_
98-38	13982-13990	inferior	_
98-39	13991-14000	occipital	_
98-40	14001-14006	gyrus	_
98-41	14007-14008	(	_
98-42	14009-14012	638	_
98-43	14013-14019	voxels	_
98-44	14020-14021	)	_
98-45	14022-14023	,	_
98-46	14024-14027	all	_
98-47	14028-14032	with	_
98-48	14033-14034	a	_
98-49	14035-14041	volume	_
98-50	14042-14047	close	_
98-51	14048-14050	to	_
98-52	14051-14054	the	_
98-53	14055-14063	thalamus	_
98-54	14064-14065	(	_
98-55	14066-14069	698	_
98-56	14070-14076	voxels	_
98-57	14077-14078	)	_
98-58	14079-14080	.	_

